Menozzi Mila, Piovaccari Giancarlo
Cardiology Unit, Infermi Hospital, Rimini.
Eur Heart J Suppl. 2020 Nov 18;22(Suppl L):L114-L116. doi: 10.1093/eurheartj/suaa148. eCollection 2020 Nov.
Coronary chronic total occlusion (CTO) produces an important clinical problem, often treated with medical therapy or coronary artery bypass grafting. Recent clinical studies, both registries and randomized trials, demonstrated that percutaneous coronary interventions (PCI), could provide a valid therapeutic option. Nonetheless, significant reduction in all-cause mortality, cardiac mortality, myocardial infarction, MACE, and MACCE has not been demonstrated in the subgroups analysis of randomized trials. These analyses suggest that PCI for CTO should be reserved for patients with angina or with large areas of the myocardium with reversible ischaemia. Large randomized studies should search for a personalized approach, considering the risks and complexity of PCI in CTO, which should mainly consider the extension of the ischaemia and the viability of the myocardium.
冠状动脉慢性完全闭塞(CTO)是一个重要的临床问题,通常采用药物治疗或冠状动脉旁路移植术进行治疗。近期的临床研究,包括登记研究和随机试验,表明经皮冠状动脉介入治疗(PCI)可以提供一种有效的治疗选择。尽管如此,在随机试验的亚组分析中,尚未证实全因死亡率、心脏死亡率、心肌梗死、主要不良心血管事件(MACE)和主要不良心血管和脑血管事件(MACCE)有显著降低。这些分析表明,CTO的PCI治疗应仅适用于心绞痛患者或存在大面积可逆性心肌缺血的患者。大型随机研究应寻求个性化的治疗方法,考虑到CTO患者PCI治疗的风险和复杂性,这主要应考虑缺血范围和心肌活力。